Management of Nitroglycerin Weaning

Introduction to Weaning

The American Heart Association recommends reducing the intravenous dose of nitroglycerin gradually and implementing intermittent dosing schemes via non-intravenous routes once the patient is stable from an ischemic standpoint 1
Continuous monitoring of blood pressure during the weaning process is crucial to avoid complications 1
The goal is to establish a blood pressure target of <130/80 mmHg before hospital discharge, while avoiding abrupt decreases in diastolic blood pressure below 60 mmHg to prevent reduced coronary perfusion and worsened ischemia 1

A gradual reduction in intravenous dose should be implemented, with small increments and monitoring of hemodynamic response after each reduction, allowing for a 15-30 minute stabilization period between each reduction 1
Transition to non-intravenous routes should occur once the patient is stable, using longer-acting nitrate formulations, and considering topical or sublingual administration as intermittent therapy 1

Tolerance to nitrates can occur even within the first 24 hours, and implementing nitrate-free periods of 10-12 hours (usually at night) can help prevent this issue 2
If transdermal patches are used, they should be applied in the morning and removed after 12-14 hours to maintain efficacy and prevent tolerance 2

The American College of Cardiology recommends considering the addition of beta-blockers if tachycardia is present during nitroglycerin use, as they are fundamental in the treatment of acute coronary syndrome for their ability to reduce heart rate and blood pressure 1, 3
Inhibitors of the angiotensin-converting enzyme (ACE) or angiotensin II receptor antagonists (ARA-II) should be initiated if the patient has a history of myocardial infarction, persistent hypertension, or evidence of left ventricular dysfunction or heart failure 4

Rapid weaning should be avoided to prevent rebound ischemia, and special caution is necessary in patients with inferior STEMI, right ventricular infarction, or those who are elderly or have volume depletion, as they are at higher risk of hypotension 1
Recent use of phosphodiesterase inhibitors (such as sildenafil within the last 24 hours or tadalafil within the last 48 hours) is also a consideration for cautious nitroglycerin use 1, 2